Nautilus Biotechnology (NAUT) Net Cash Flow (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Net Cash Flow of -$1.5 million for Q2 2026, down 165.24% sequentially from $2.2 million in Q1 2026, and down 219.77% YoY from $1.2 million in Q2 2025.
Nautilus Biotechnology (NAUT) Net Cash Flow (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Net Cash Flow for 7 years, with the latest figure at -$1.5 million in Q2 2026.
- Quarterly Net Cash Flow fell 219.77% year-over-year to -$1.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$21.3 million (down 322.43% YoY) and the FY2025 annual result came in at -$15.3 million, down 284.97% from the prior year.
- Net Cash Flow slipped to -$1.5 million in Q2 2026 per NAUT's latest filing, from $2.2 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $23.2 million in Q4 2024 and troughed at -$74.3 million in Q4 2022.
- A 5-year average of -$9.6 million and a median of -$1.2 million in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow slumped 1613.38% in 2024, then jumped 244.43% in 2025.
- Over 5 years, Net Cash Flow stood at -$74.3 million in 2022, then advanced by 26.37% to -$54.7 million in 2023, then soared by 142.48% to $23.2 million in 2024, then plunged by 149.43% to -$11.5 million in 2025, then surged by 87.29% to -$1.5 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$1.5 million, $2.2 million, and -$11.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Nautilus Biotechnology | 114.43 Mn | 114.43 Mn | 175,000.00 | -1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.46 Mn |
| Jun 30, 2026 | -1.46 Mn |
| Mar 31, 2026 | 2.24 Mn |
| Mar 31, 2026 | 2.24 Mn |
| Dec 31, 2025 | -11.49 Mn |
| Dec 31, 2025 | -11.49 Mn |
| Sep 30, 2025 | -10.58 Mn |
| Sep 30, 2025 | -10.58 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 5.59 Mn |
| Mar 31, 2025 | 5.59 Mn |
| Dec 31, 2024 | 23.24 Mn |
| Dec 31, 2024 | 23.24 Mn |
| Sep 30, 2024 | -20.48 Mn |
| Sep 30, 2024 | -20.48 Mn |
| Jun 30, 2024 | -844,000.00 |
| Jun 30, 2024 | -844,000.00 |
| Mar 31, 2024 | 6.33 Mn |
| Mar 31, 2024 | 6.33 Mn |